NCT05470712

Brief Summary

Formation of neutrophil extracellular traps (NETs) is a process of activation of neutrophils, which then generate filaments containing DNA, enzymes and extracellular histones. Two mechanisms of formation of NETs are described in the literature: vital mechanism via Toll Like Receptors (TLRs) and suicidal mechanism, dependent on the reactive oxygen species (ROS) pathway. The description of these two mechanisms of formation of NETs is recent and no data exist in the context of pregnancy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
26

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jul 2022

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 20, 2022

Completed
Same day until next milestone

Study Start

First participant enrolled

July 20, 2022

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 22, 2022

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2022

Completed
Last Updated

December 4, 2025

Status Verified

February 1, 2023

Enrollment Period

5 months

First QC Date

July 20, 2022

Last Update Submit

November 26, 2025

Conditions

Keywords

PregnancyPre-eclampsiaNeutrophilsExtracellular traps

Outcome Measures

Primary Outcomes (1)

  • To evaluate vital mechanism of NETs formation between pregnant women with normal pregnancies and those developing preeclampsia.

    Evaluation of vital mechanism of NETs formation between pregnant women with normal pregnancies and those developing preeclampsia.

    3 months

Secondary Outcomes (8)

  • To compare the proportion of vital mechanism of NETs formation in the presence or absence of a TLR-blocking antibody within each group: normal pregnancy and preeclamptic pregnancy.

    3 months

  • To compare the proportion of vital mechanism of NETs formation in the presence of a TLR-blocking antibody between pregnant women with normal pregnancies and those developing preeclampsia.

    3 months

  • To compare vital and suicidal mechanisms of NETs formation between pregnant women with a normal pregnancy and those developing preeclampsia.

    3 months

  • To compare vital and suicidal mechanisms of NETs formation in the presence or absence of a TLR blocking antibody or ROS inhibitor (DPI) separately within each group: normal pregnancy and preeclamptic pregnancy.

    3 months

  • To compare vital and suicidal mechanisms of NETs formation in the presence of TLR blocking antibody or ROS inhibitor (DPI) between pregnant women with normal pregnancy and those developing preeclampsia.

    3 months

  • +3 more secondary outcomes

Study Arms (2)

Plasma from women with preeclampsia

Plasma collected from women who developed preeclampsia during pregnancy will be analyzed for mechanism of NETs formation.

Plasma from women with normal pregnancies

Plasma collected from women with normal pregnancies will be analyzed for mechanism of NETs formation.

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Gender Eligibility Detailsfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study is based on frozen plasma samples from pregnant women, taken at the time of them giving birth from among the 85 women who constituted the previous cohort (NCT01736826). Thirteen of these women had had normal pregnancies and thirteen had developed pre-eclampsia. Cases are matched on maternal age, clinical event (delivery) and gestational age will be included from the previous cohort (NCT01736826).

You may qualify if:

  • pregnant women followed at Nimes University hospital for normal pregnancy or pregnancy with placental vascular pathology (pre-eclampsia and/or intra-uterine growth retardation).
  • The patient must have given her free and informed consent and signed the consent form.
  • The patient must be a member or beneficiary of a health insurance plan
  • Only women are included
  • Patients are at least 18 years old

You may not qualify if:

  • twin pregnancies.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU Nimes

Nîmes, 30029, France

Location

Related Publications (1)

  • Guillotin F, Fortier M, Portes M, Demattei C, Mousty E, Nouvellon E, Mercier E, Chea M, Letouzey V, Gris JC, Bouvier S. Vital NETosis vs. suicidal NETosis during normal pregnancy and preeclampsia. Front Cell Dev Biol. 2023 Jan 5;10:1099038. doi: 10.3389/fcell.2022.1099038. eCollection 2022.

Biospecimen

Retention: SAMPLES WITHOUT DNA

This study is based on the NETs formation mechanism of frozen plasma samples from patients included in a previous cohort (RCB 2014-A01120-47, NCT01736826). The benefits will ultimately be a better understanding of the physiopathological mechanisms involved in the occurrence of this placental vascular pathology

MeSH Terms

Conditions

Pre-Eclampsia

Condition Hierarchy (Ancestors)

Hypertension, Pregnancy-InducedPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Study Officials

  • Anissa MEGZARI

    CHU Nimes

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 20, 2022

First Posted

July 22, 2022

Study Start

July 20, 2022

Primary Completion

December 31, 2022

Study Completion

December 31, 2022

Last Updated

December 4, 2025

Record last verified: 2023-02

Locations